
Phio Pharmaceuticals Corp.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Phio Pharmaceuticals develops RNAi-based therapeutics designed to weaken tumor defenses and enhance the ability of immune cells to fight cancer, using its self-delivering RNAi (INTASYL) platform.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Plott Ronald ToddDirector | Buy | $17K | 15,000at $1.14 | Aug 19, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PHIO activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.